Shares of Quantinuum surged 10.6% to $36.53 on Oct. 15 after Morgan Stanley analyst Joseph Moore upgraded the stock to Overweight from Equalweight and named it the bank's top quantum-computing pick. Morgan Stanley said Quantinuum leads pure-play quantum peers in technology and execution, while the market assigns it the lowest multiple of the bank's 2030 revenue projections in the group. The rally arrived as the stock sat near its 52-week low of $33.02, down significantly from its 52-week high of $86.79 — a decline of more than 60% from its July peak.

  • The Upgrade Comes With a Catch: A Lower Price Target. Morgan Stanley upgraded Quantinuum from Equal-Weight to Overweight, but the price target was lowered from $78 to $62 — a 20.5% cut. That still implies roughly 70% upside from today's price, but the reduction signals that even the bull case has been marked down as broader tech valuations compress. In other words, Morgan Stanley likes the company more relative to peers but is less optimistic about what the whole sector is worth.

  • A $100 Billion Market That Barely Exists Yet. Morgan Stanley estimates quantum computing could represent a market exceeding $100 billion by 2040 and developed a proprietary framework to evaluate companies across technical progress, execution, manufacturability, and broader indicators. Quantinuum scored highest, but investors are buying a promise: Q2 2026 revenue surged 279% year-over-year to $8M, strategic partnerships including a major Oracle deal fueled momentum, and 2026 revenue guidance was raised to $28–$32M. That's real growth off a tiny base — yet the stock still trades at a price-to-sales ratio near 140x, making it a pure bet on future breakthroughs.

  • 2027 Is the Make-or-Break Year. Moore flagged 2027 as a key test year, when Quantinuum's next-generation quantum computer is expected to show how far the technology can scale. If the hardware delivers, it could justify the lofty valuation; if it stumbles, today's stock price — already down 39% since its June IPO — has further to fall. The company posted a net loss of $733.1 million in just the first half of 2026 , underscoring the cash-burn reality.

  • Peers Got No Love. Morgan Stanley kept rival IonQ at Equalweight and initiated coverage of two other quantum firms at Equalweight , making Quantinuum the only upgrade. That relative endorsement matters in a sector where no company has proven commercial viability; the distinction may steer institutional capital toward QNT specifically as a category winner.

The bottom line: A Wall Street stamp of approval halted a brutal slide, but shareholders are still paying a steep premium for technology that won't generate meaningful revenue for years.